Sugi Predict

Sugi Predict / Compounds / SCHEMBL10176111

SCHEMBL10176111

SCHEMBL10176111

COC(=O)CS(=O)(=O)N(C)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.43
▸ PTPN1 P18031 1/20 0.43
▸ PTPN6 P29350 1/20 0.43
▸ PTPN11 Q06124 1/20 0.43
▸ KMT2A Q03164 4/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ POLB P06746 2/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ NAMPT P43490 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CA12 O43570 2/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ MCHR1 Q99705 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ NR1I2 O75469 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2888746 0.82 CA12 (0.44) TSHRKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL13762631 0.80 MMP3 (0.57) TSHRKMT2AMEN1POLBSMN1; SMN2
SCHEMBL1403193 0.79 LMNA (0.44) TSHRPTPN1PTPN6PTPN11SMN1; SMN2
SCHEMBL1403165 0.79 LMNA (0.44) TSHRPTPN1PTPN6PTPN11SMN1; SMN2
SCHEMBL7308150 0.76 KCNA5 (0.44) TSHRKMT2APOLBSMN1; SMN2MAPT
SCHEMBL5804742 0.75 CA12 (0.44) TSHRKMT2AMEN1POLBHTT
SCHEMBL7309475 0.75 MMP3 (0.60) TSHRLMNAALDH1A1CA12CA9
SCHEMBL7318436 0.75 KCNN4 (0.40) TSHRPOLBMAPTLMNAHTT
SCHEMBL15672856 0.74 CA12 (0.50) TSHRKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL13762630 0.74 CA12 (0.50) TSHRKMT2AMEN1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-10-14 — — US disclosed
US-20230078513-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF SHIRE HUMAN GENETIC THERAPIES, INC. 2023-03-16 — — US disclosed
US-11352356-B2 Inhibitors of plasma kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-06-07 — — US disclosed
US-11352356-B2 Inhibitors of plasma kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-06-07 — — US disclosed
EP-3765459-A1 SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF Shire Human Genetic Therapies, Inc. (US) 2021-01-20 — — EP disclosed
CN-112135825-A Plasma kallikrein inhibitors and uses thereof 夏尔人类遗传性治疗公司 2020-12-25 — — CN disclosed
US-20200317667-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF SHIRE HUMAN GENETIC THERAPIES, INC. 2020-10-08 — — US disclosed
US-20200317667-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF SHIRE HUMAN GENETIC THERAPIES, INC. 2020-10-08 — — US disclosed
US-10730874-B2 Inhibitors of plasma kallikrein and uses thereof SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2020-08-04 — — US disclosed
US-10730874-B2 Inhibitors of plasma kallikrein and uses thereof SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2020-08-04 — — US disclosed
WO-2014198849-A1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2014-12-18 — — WO disclosed
US-8222269-B2 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-07-17 — — US disclosed
US-8222269-B2 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-07-17 — — US disclosed
US-8101603-B2 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-01-24 — — US disclosed
US-8101603-B2 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-01-24 — — US disclosed
US-20090203684-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2009-08-13 — — US disclosed
US-20090203684-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2009-08-13 — — US disclosed
US-20090012076-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2009-01-08 — — US disclosed
US-20090012076-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2009-01-08 — — US disclosed
WO-2008008310-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352356-B2 Inhibitors of plasma kallikrein and uses thereof KLKB1, KLK1, KLK5 TSHR 4177/4885PTPN1 2633/4885PTPN6 2613/4885
US-20090012076-A1 Tyrosine kinase inhibitors ABL1, ERBB2, MET TSHR 1677/4885PTPN1 66/4885PTPN6 84/4885
US-10730874-B2 Inhibitors of plasma kallikrein and uses thereof KLKB1, KLK1, KLK5 TSHR 4177/4885PTPN1 2633/4885PTPN6 2613/4885
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof KLKB1, KLK1, KLK5 TSHR 4177/4885PTPN1 2633/4885PTPN6 2613/4885
US-20200317667-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF KLKB1, KLK1, KLK5 TSHR 4177/4885PTPN1 2633/4885PTPN6 2613/4885
US-20090203684-A1 Tyrosine kinase inhibitors ABL1, MET, ERBB2 TSHR 1817/4885PTPN1 98/4885PTPN6 123/4885
US-20230078513-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF KLKB1, KLK1, KLK5 TSHR 4177/4885PTPN1 2633/4885PTPN6 2613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.